ATTCK 20

Drug Profile

ATTCK 20

Alternative Names: Antibody-coupled T-cell receptor anti-CD20 immunotherapy - Unum-Therapeutics; ATTCK20; mRNA ACTR T-cells + rituximab

Latest Information Update: 31 Dec 2015

Price : $50

At a glance

  • Originator Unum Therapeutics
  • Developer National University Hospital (Singapore); Singapore General Hospital; Unum Therapeutics
  • Class Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2015 Unum Therapeutics plans a phase I trial for Non-Hodgkin lymphoma (Second-line therapy or greater) in USA
  • 01 Dec 2014 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in Singapore (Parenteral)
  • 01 Dec 2014 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Singapore (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top